Nuvilex, Inc. (OTCQB:NVLX), an emerging biotechnology provider of cell and gene therapy solutions, today announced that it has executed a consulting agreement with Dawson James Financial Services, Inc. The agreement is seen as a key step as the company moves forward with closing the SG Austria asset acquisition.
Chief Executive Officer Dr. Robert Ryan commented, “We’ve been working closely with SG Austria over the past several months to develop the cell encapsulation technology and to focus on preparing that technology for market for stem cell therapy, for treating diabetes and pancreatic cancer. With the recent consolidation of the patent rights under the SG Austria roof, we are now finally in a position to move forward with the previously executed asset purchase agreement.”
Dr. Ryan added, “We are dedicated to completing development of the encapsulation technology for stem cell therapy and diabetes, all at the same time while gearing up for Phase 2 and 3 clinical trials for the pancreatic cancer treatment which is paramount to our immediate business goals. Thus, completing the SG Austria asset acquisition, bringing clinical trial preparations to fruition, and initiating the clinical trials are our top priorities.”
Nuvilex, Inc. (OTCQB:NVLX) is an emerging international biotechnology provider of live therapeutically valuable, encapsulated cells and services for research and medicine. Substantial effort for our corporate activities in concert with SG Austria is near completion and will drive our strong future together. Our Company’s clinical offerings will include cancer, diabetes and other treatments using the Company’s industry-leading cell and gene therapy expertise and cutting edge, live-cell encapsulation technology.
Safe Harbor Statement
This press release contains forward-looking statements described within the Private Securities Litigation Reform Act of 1995 involving risks and uncertainties including product demand, market competition, and meeting current or future plans which may cause actual results, events, and performances, expressed or implied, to vary and/or differ from those contemplated or predicted. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Nuvilex is not obliged to publicly release revisions to any forward-looking statement, reflect events or circumstances afterward, or disclose unanticipated occurrences, except as required under applicable laws.Business Wire
Last updated on: 01/05/2012